Goldman Sachs Group Inc. Takes Position in Bicycle Therapeutics PLC Sponsored ADR $BCYC

Goldman Sachs Group Inc. bought a new stake in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 25,192 shares of the company’s stock, valued at approximately $214,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Long Focus Capital Management LLC boosted its stake in shares of Bicycle Therapeutics by 138.2% in the first quarter. Long Focus Capital Management LLC now owns 1,293,753 shares of the company’s stock valued at $10,984,000 after buying an additional 750,661 shares during the period. Armistice Capital LLC boosted its stake in shares of Bicycle Therapeutics by 21.7% in the first quarter. Armistice Capital LLC now owns 2,672,000 shares of the company’s stock valued at $22,685,000 after buying an additional 476,000 shares during the period. Jefferies Financial Group Inc. bought a new stake in shares of Bicycle Therapeutics in the first quarter valued at approximately $3,471,000. Woodline Partners LP bought a new stake in shares of Bicycle Therapeutics in the first quarter valued at approximately $3,088,000. Finally, Millennium Management LLC boosted its stake in shares of Bicycle Therapeutics by 156.5% in the first quarter. Millennium Management LLC now owns 453,428 shares of the company’s stock valued at $3,850,000 after buying an additional 276,671 shares during the period. Institutional investors and hedge funds own 86.15% of the company’s stock.

Analyst Ratings Changes

BCYC has been the subject of several recent research reports. Oppenheimer reiterated an “outperform” rating and issued a $44.00 price target (down from $48.00) on shares of Bicycle Therapeutics in a research note on Monday, August 11th. JMP Securities cut their price target on Bicycle Therapeutics from $22.00 to $10.00 and set a “market outperform” rating for the company in a research note on Tuesday, August 12th. Royal Bank Of Canada set a $27.00 price target on Bicycle Therapeutics and gave the company an “outperform” rating in a research note on Monday, August 11th. Finally, Morgan Stanley cut their target price on Bicycle Therapeutics from $17.00 to $13.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 12th. Six analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $22.22.

Bicycle Therapeutics Price Performance

NASDAQ BCYC opened at $7.40 on Monday. The business has a fifty day moving average price of $7.49 and a two-hundred day moving average price of $7.86. Bicycle Therapeutics PLC Sponsored ADR has a fifty-two week low of $6.10 and a fifty-two week high of $28.67. The stock has a market capitalization of $512.89 million, a PE ratio of -2.11 and a beta of 1.41.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Friday, August 8th. The company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.95) by ($0.19). Bicycle Therapeutics had a negative return on equity of 32.43% and a negative net margin of 1,257.00%.The business had revenue of $2.90 million for the quarter, compared to the consensus estimate of $9.43 million. As a group, sell-side analysts expect that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 earnings per share for the current year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.